FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileProthena Corporation plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PRTA
Prothena Corporation plc Stock AnalysisComprehensive stock analysis for Prothena Corporation plc (PRTA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPRTA
PRTA
Prothena Corporation plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PRTA
  1. Home
  2. Stocks
  3. Prothena Corporation plc

Prothena Corporation plc

🇺🇸PRTA•NASDAQ

Prothena Corporation plc

🇺🇸PRTA•NASDAQ
Market cap
$409.26M
Sentiment

Your view on PRTA

Mkt Cap
$409.26M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Prothena Corporation plc

Industry
Biotechnology
Sector
Healthcare
CEO
Gene G. Kinney
Headquarters
77 Sir John Rogerson’s Quay, Dublin, IE
Industry
Biotechnology
Sector
Healthcare
CEO
Gene G. Kinney
Headquarters
77 Sir John Rogerson’s Quay, Dublin, IE
Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.

The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.

Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.

The company was founded in 2012 and is based in Dublin, Ireland.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Prothena Corporation plc from FRC's valuation model, read against the market price. PRTA last traded at $7.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Prothena Corporation plc. Starting points for Prothena Corporation plc: EPS -$0.47, beta -0.33 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Prothena Corporation plc. Prothena Corporation plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Prothena Corporation plc. Trailing twelve-month EPS for Prothena Corporation plc stands at -$0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$21.75

average of 4 firms, last 12 months

 

$21.75

Low $19.00

Median $19.00

High $30.00

 

Analyst Ratings

Buy28 ratings
  • Strong Buy0
  • Buy20
  • Hold6
  • Sell2
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.02-$0.37-$0.02-$1.02
Low estimate$0.01-$0.38-$0.15-$1.36
High estimate$0.03-$0.36$0.11-$0.40
No. of analysts2144
Year-ago EPS-$0.44$0.601-$4.53—
Growth+105.5%—+99.5%—

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$19.92M$581169.00$72.42M$24.54M
Low estimate$451006.00$13160.00$47.98M$19.74M
High estimate$39.37M$1.15M$96.88M$31.59M
No. of analysts4255
Year-ago revenue$21000.00$51.08M$9.68M—
Growth+94737.4%-98.9%+647.9%—
Recent analyst actions15 rating and price-target changes, latest Jul 24, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Prothena Corporation plc. Prothena Corporation plc has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PRTA20 companies · 8 funds
Compare PRTA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABOSAcumen Pharmaceuticals, Inc.Biotechnology$16M
  • ACIUAC Immune S.A.Biotechnology$213M
  • ANNXAnnexon, Inc.Biotechnology$585M
  • AVXLAnavex Life Sciences Corp.Biotechnology$76M
  • BIIBBiogen Inc.Drug Manufacturers - General$37.2B
  • CGTXCognition Therapeutics, Inc.Biotechnology$61M
  • DNLIDenali Therapeutics Inc.Biotechnology$2.9B
  • NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M

More Biotechnology companies

  • OCSOculis Holding AGNASDAQ$471M
  • MGNXMacroGenics, Inc.NASDAQ$139M
  • MGTXMeiraGTx Holdings plcNASDAQ$854M
  • MGXMetagenomi, Inc. Common StockNASDAQ$26M
  • MIR.VMedMira Inc.TSXV$16M
  • MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
  • MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
  • MLECMoolec Science S.A.NASDAQ$617,200
  • MLECWMoolec Science S.A.NASDAQ$76,243
  • MLLCFMolecular Partners AGOTC$131M
  • MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
  • MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B

ETFs holding Prothena Corporation plc

% of the fund

  • IWMiShares Russell 2000 ETF$76.6B in assets0.01%
  • XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.08%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • DFASDimensional - US Small Cap ETF$33.7B in assets0.01%
  • BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets0.79%
  • QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.52%
  • FSCCFederated Hermes MDT Small Cap Core ETF$496M in assets0.41%
  • GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF$1.0B in assets0.04%

Largest holders first, then the funds most concentrated in PRTA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Prothena Corporation plc, and how their positions are changing. At a $409.3M market value, institutional positions materially move Prothena Corporation plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Prothena Corporation plc executives and directors. Shares of Prothena Corporation plc have traded between $4.32 and $17.66 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Prothena Corporation plc. Coverage tracks Prothena Corporation plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Prothena Corporation plc.

PRTA Analysis
Fair
Past4
Growth1
Health5
Profit1
Value1

News

Latest Market News